BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14761837)

  • 1. Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology.
    Hafez B; Hafez ES
    Arch Androl; 2004; 50(2):45-68. PubMed ID: 14761837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology.
    Kaplan SA
    J Urol; 2005 Jun; 173(6):2058-9. PubMed ID: 15879831
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel treatment options for overlapping yet distinct erectile dysfunction and andropause syndromes.
    Tan RS
    Curr Opin Investig Drugs; 2003 Apr; 4(4):435-8. PubMed ID: 12808883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Andropause, male climacteric and crisis of the fifties: should androgens be administered?].
    Martin-Du Pan R; Martin-du Pan S; Sindelar P
    Rev Med Suisse Romande; 1995 Mar; 115(3):257-62. PubMed ID: 7777768
    [No Abstract]   [Full Text] [Related]  

  • 5. Male andropause: myth, reality, and treatment.
    Wespes E; Schulman CC
    Int J Impot Res; 2002 Feb; 14 Suppl 1():S93-8. PubMed ID: 11850741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 5 alpha-reductase inhibitors on erectile function.
    Canguven O; Burnett AL
    J Androl; 2008; 29(5):514-23. PubMed ID: 18421068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal supplementation and erectile dysfunction.
    Aversa A; Isidori AM; Greco EA; Giannetta E; Gianfrilli D; Spera E; Fabbri A
    Eur Urol; 2004 May; 45(5):535-8. PubMed ID: 15082192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Andropause: myth or reality?].
    Tomer Y; Lunenfeld B; Berezin M
    Harefuah; 1995 Jun; 128(12):785-8. PubMed ID: 7557690
    [No Abstract]   [Full Text] [Related]  

  • 9. Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.
    Hafez ES; Hafez SD
    Arch Androl; 2005; 51(1):15-31. PubMed ID: 15764414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between hypogonadism and erectile dysfunction.
    Hwang TI; Lin YC
    Int J Impot Res; 2008; 20(3):231-5. PubMed ID: 18305486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
    Morgunov LIu; Vertkin AL; Pushkar' DIu
    Urologiia; 2007; (5):49-51. PubMed ID: 18254226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The andropause: fact or fiction?
    Burns-Cox N; Gingell C
    Postgrad Med J; 1997 Sep; 73(863):553-6. PubMed ID: 9373594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.
    Cavallini G; Caracciolo S; Vitali G; Modenini F; Biagiotti G
    Urology; 2004 Apr; 63(4):641-6. PubMed ID: 15072869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on erectile dysfunction in prostate cancer patients.
    Kendirci M; Bejma J; Hellstrom WJ
    Curr Opin Urol; 2006 May; 16(3):186-95. PubMed ID: 16679857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of the cardinal features of andropause.
    Mooradian AD; Korenman SG
    Am J Ther; 2006; 13(2):145-60. PubMed ID: 16645432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [RNA interference and its application in andrology research].
    Wan H; Xiong CL
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):545-9. PubMed ID: 18649757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.
    Miller DC; Wei JT; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin PW; Sanda MG
    Urology; 2006 Jul; 68(1):166-71. PubMed ID: 16844457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study.
    Stephenson RA; Mori M; Hsieh YC; Beer TM; Stanford JL; Gilliland FD; Hoffman RM; Potosky AL
    J Urol; 2005 Aug; 174(2):646-50; discussion 650. PubMed ID: 16006930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.